12 peptide categories

GLP-1 and multi-receptor agonists behind the modern obesity and diabetes wave — semaglutide, tirzepatide, retatrutide — plus metabolic compounds catalogued alongside them.

GHRH analogs, ghrelin-receptor secretagogues, IGF-1 variants, and myostatin inhibitors that modulate the GH axis and skeletal-muscle growth signaling.

BPC-157, Thymosin beta-4 (TB-500), and related peptides studied for soft-tissue repair, wound healing, and recovery from connective-tissue injury.

Peptides targeting cognition, mood, and neuroprotection — Semax, Selank, Cerebrolysin, PT-141, and other CNS-active research compounds.

Topical peptides for dermal and cosmetic research — GHK-Cu, Argireline, Matrixyl, and the melanocortin agonists Melanotan I and II.

Epitalon, Khavinson short-peptide bioregulators, FOXO4-DRI, and longevity cofactors (NAD+, glutathione) studied for aging and tissue-specific regeneration.

Thymic peptides (Thymalin, Thymulin, Thymosin alpha-1), cathelicidins (LL-37), and alpha-MSH-derived fragments studied for immune modulation and inflammatory-pathway research.

Mitochondria-targeted peptides and small molecules — SS-31 (FORZINITY), MOTS-c, 5-Amino-1MQ, and the ERR agonist SLU-PP-332 — studied for energy metabolism and mitochondrial dysfunction.

GnRH receptor agonists (Gonadorelin), kisspeptin, oxytocin, and PTH fragments (Teriparatide) — peptides that act directly on endocrine-axis receptors.

Peptides and small molecules studied for sexual function — melanocortin-receptor agonists (PT-141 / bremelanotide), premature-ejaculation SSRIs (dapoxetine), and related compounds acting on libido, arousal, or ejaculatory latency.

Novel and early-stage research peptides with unresolved classification or limited preclinical data. Not approved for any use.

Solvents and diluents used to dissolve lyophilized research peptides before use. Not peptides themselves — the fluid that turns the vial powder into an injectable solution.